All
Jurczak on BTK Inhibitors and the Future of B-Cell Lymphoma Therapy
Wojciech Jurczak, MD, PhD, discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders.
Advancements in Precision Radiation Treatment With the MR-LINAC
Paul B. Renz, DO, discusses anecdotal changes observed by clinician researchers using the MR-LINAC system.
Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC
A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.
FDA Clears IND Application for EVM14 Across Cancers
The FDA has cleared EVM14, making it the first mRNA therapeutic cancer vaccine for global clinical trials.
The MR-LINAC System Allows for Customization of Radiation Treatment
Paul B. Renz, DO, discusses the ideal uses of magnetic resonance-guided linear accelerator system.
“Nutrition Is Crucial”: Enhancing Cancer Treatment and Survivorship Through Dietary Strategies
For Nutrition Awareness Month, we highlight the importance of tailoring dietary strategies to patients with cancer to improve outcomes and quality of life.
New AI Tool Predicts Prostate Cancer Treatment Success
A recent study suggests that using artificial intelligence to measure tumor size could reduce treatment failures by more than 70%.
Redefining Mesothelioma and Addressing Persistent Challenges
Hedy Lee Kindler, MD, shares new mesothelioma guidelines that have been released by the American Society of Clinical Oncology.
The Targeted Pulse: Excellent Advancements in Breast Cancer Management and an Extended Access Program for NMIBC
Positive data and developments to be aware of in AML, breast cancer, PDAC, and NMIBC.
The Evolution of BTK Inhibitors in B-Cell Lymphoma
Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.
Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma
Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.
The Promise of OBX-115, a Novel TIL Therapy, in Melanoma
Rodabe Amaria, MD, discusses the current role of OBX-115 for the treatment of patients with checkpoint inhibitor-resistant metastatic melanoma.
Extended PSA Monitoring Post-Prostatectomy May Reduce Overtreatment, Study Finds
Investigators found that higher persistent PSA levels after surgery were linked to a worse prognosis, underscoring the importance of timing in post-operative care.
The Shrinking Oncology Workforce and Its Impact on Supply and Demand
With changes in demographics and advancements in cancer care, the current oncologist workforce is expected to experience an imbalance in supply and demand.
Nemtabrutinib Shows Promise in Relapsed/Refractory Follicular Lymphoma
Wojciech Jurczak, MD, PhD, discusses nemtabrutinib and its development for the treatment of follicular lymphoma.
FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer
PEP-010 was granted FDA orphan drug designation for the treatment of pancreatic cancer.
FDA OKs TLX007-CDx in Prostate Cancer Treatment
TLX007-CDx is now an FDA-approved PSMA PET imaging agent in prostate cancer.
FDA Updates Decision on ProSense Cryoablation for Early-Stage Breast Cancer
The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected after the first quarter of 2025.
ST316 Shows Promise in Phase 1 Trial for Wnt/β-Catenin-Driven Cancers
ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid tumors.
Tislelizumab Gains FDA Nod in Advanced Esophageal Cancer
Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or higher.
Pembrolizumab Plus Bevacizumab Shows Promise for Melanoma Brain Metastases
The anti–PD-1/VEGF combination of pembrolizumab and bevacizumab elicited strong clinical activity in patients with melanoma brain metastases.
Amaria Highlights Phase 1 Trial of OBX-115 in Melanoma
Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint inhibitor-resistant metastatic melanoma.
FDA Grants Standard Approval to Pembrolizumab Plus Trastuzumab/Chemo for HER2+, PD-L1+ Gastric Cancer
The combination of pembrolizumab, trastuzumab, and chemotherapy is now approved in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
FDA Grants Orphan Drug Designation to HLX22 for Gastric Cancer Treatment
The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line treatment.
Tarlatamab Demonstrates Positive Benefit-Risk Profile in SCLC
Tarlatamab showed a positive benefit-risk profile in small cell lung cancer, per the phase 2 DeLLphi-301 study.
FDA Backs Phase 3 Trial of Pro-ocular for Ocular GVHD Treatment
A phase 3 trial plans to evaluate Pro-ocular for the treatment of patients with ocular graft-vs-host disease.
Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma
Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.
Shortened Radiation Trial Advances Breast Cancer Treatment
M. Michele Blackwood, MD, FACS, highlights an innovative trial delivering 1 week of pre-surgery and 2 weeks of post-surgery radiation for patients with breast cancer.
Bexobrutideg Gains FDA Orphan Drug Status in Waldenström Macroglobulinemia
Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in Waldenström macroglobulinemia.
Amivantamab/Lazertinib Efficacy in EGFR+ NSCLC Sustained in MARIPOSA Follow-Up
Shirish M. Gadgeel, MD, discussed long-term data from the MARIPOSA trial of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.
